CD8A and neoplasm: This dual-axis alteration reduces CD8+ T cell cytotoxicity, limits effector cell recruitment, and promotes angiogenesis via vascular endothelial growth factor VEGF-expressing M2 macrophages, driving tumor progression and resistance to immune clearance [25].